MetaCap

Axogen (AXGN) vs CapsoVision (CV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Axogen (AXGN) has outperformed CapsoVision (CV) over the past year, gaining 107.5% versus a gain of 16.8%. Axogen is the larger company by market cap ($3.33 billion vs $327.6 million), about 10.2 times the size. Axogen converts more of its revenue into profit, with a net margin of -7.0% versus -186.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AXGN+107.48%CV+16.83%
+185%+82%-21%
Nov 21, 20251 yearNov 20, 2026
AXGN+410.06%CV+38.86%
+433%+197%-40%
Jun 30, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AXGN versus CV key metrics
MetricAXGNCV
Share price$55.75$6.11
Market cap$3.33B$327.56M
1-day change-1.06%-3.17%
YTD return+70.33%-42.84%
1-year return+107.48%+16.83%
5-year return+481.33%—
Forward P/E79.03—
EPS (TTM)$-0.63$-0.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$225.21M$13.55M
Revenue growth (YoY)+20.21%+15.29%
Net income (latest FY)$-15.70M$-25.32M
Gross margin74.31%52.92%
Operating margin-3.49%-188.25%
Net margin-6.97%-186.77%
52-week high$59.72$15.37
52-week low$26.92$4.50
Distance from 52-week high-6.65%-60.25%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+6.31%+55.48%
Average volume1.57M173.59K
Shares outstanding59.73M53.61M
Employees62299
SectorHealth CareHealth Care
IndustryBiotechnology: Electromedical & Electrotherapeutic ApparatusBiotechnology: Electromedical & Electrotherapeutic Apparatus

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Axogen is about 10.2 times larger than CapsoVision by market value ($3.33B vs $327.56M).
  • AXGN has outperformed CV by 90.7 percentage points over the past year.
  • Axogen is more profitable, keeping -7.0 cents of every revenue dollar as net income versus -186.8 cents for CapsoVision.

About Axogen

AXGN stock →

Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps.

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 622 employees

About CapsoVision

CV stock →

CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon).

Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 99 employees

AXGN vs CV FAQ

Which is bigger, Axogen or CapsoVision?

Axogen (AXGN) is larger, with a market capitalization of $3.33B compared with $327.56M for CapsoVision (CV).

Which stock has performed better over the past year, AXGN or CV?

AXGN returned +107.48% over the past 12 months, compared with +16.83% for CV (price return, excluding dividends). Past performance does not predict future results.

Are Axogen and CapsoVision in the same industry?

Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.

More comparisons